BDBM246234 US10183932, Example 139::US9434690, 139::US9822102, Example 139

SMILES CCC1(CC(C(=O)Nc2ccc(cc2)-c2noc(=O)[nH]2)n2cc(OC)c(cc2=O)-c2cc(Cl)ccc2C#N)COC1

InChI Key InChIKey=GNLXHDHFJKLSJD-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 246234   

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246234(US9434690, 139 | US10183932, Example 139 | US98221...)
Affinity DataIC50: 2.5nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246234(US9434690, 139 | US10183932, Example 139 | US98221...)
Affinity DataIC50: 9.40nMpH: 7.4 T: 2°CAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/28/2017
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246234(US9434690, 139 | US10183932, Example 139 | US98221...)
Affinity DataIC50: 2.5nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246234(US9434690, 139 | US10183932, Example 139 | US98221...)
Affinity DataIC50: 9.40nMAssay Description:To determine the factor XIa inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reaction of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/16/2019
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246234(US9434690, 139 | US10183932, Example 139 | US98221...)
Affinity DataIC50: 2.5nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM246234(US9434690, 139 | US10183932, Example 139 | US98221...)
Affinity DataIC50: 9.40nMAssay Description:Test substances are dissolved in dimethyl sulphoxide and serially diluted in dimethyl sulphoxide (3000 μM to 0.0078 μM; resulting final con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2019
Entry Details
Go to US Patent